Drug Type siRNA |
Synonyms pan-KRAS centyrin-siRNA conjugates, ABX-300 |
Target |
Mechanism KRAS inhibitors(GTPase KRas inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization Aro Biotherapeutics Co.Startup |
Active Organization- |
Inactive Organization Aro Biotherapeutics Co.Startup |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Immune System Diseases | Preclinical | US | Aro Biotherapeutics Co.Startup | 11 Dec 2018 |
KRAS mutation-related tumors | Preclinical | US | Aro Biotherapeutics Co.Startup | 11 Dec 2018 |
Muscular Diseases | Preclinical | US | Aro Biotherapeutics Co.Startup | 11 Dec 2018 |